The clinical significance of serum soluble fas and p53 protein in breast cancer patients: Comparison with serum CA 15-3

Pathology and Oncology Research

Volumn 18, Issue 4, 2012, Pages 841-848

  Hewala, Taha I ^a   El Monaim, Nadia A Abd ^a   Anwar, Medhat ^a   Ebied, Samia A ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Apoptosis; Breast cancer; CA 15 3; Diagnosis; FAC chemotherapy; P53 protein; Soluble Fas; Surgery

Indexed keywords

CA 15-3 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FAS ANTIGEN; FLUOROURACIL; PROTEIN P53;

ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT MONITORING; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; UPREGULATION;

ADULT; ANTIGENS, CD95; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84868446077     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-012-9512-1     Document Type: Article

References (29)

1. Tamakoshi IA, Nakachi K, Ito Y, Lin Y, Yagyu K, Kikuchi IS, et al (2008) Soluble Fas level and cancer mortality: Findings from a nested case-control study within a large-scale prospective study. Int. J. Cancer 123: 1913-1916.
2. Sheen-Chen SM, Chen HS, Eng HL, Chenw J (2003) Circulating soluble Fas in patients with breast cancer. World J Surg 27:10-13
3. Jager J, Jansen R, Arends J (2002) Clinical relevance of apoptotic markers in breast cancer not yet clear. Apoptosis 7:361-365
4. Evan G, Littlewood T (1998) A matter of life and cell death. Science 94:695-698
5. Kolomecki K, Maciaszczyk P, Stepien T, Kuzdak K, Ulanska J (2005) p53 concentration and soluble FasL(sFasL) serum level as indicators of apoptosis in patients with benign and malignant thyroid tumors. Bratisl Lek Listy 106:297-300
6. Bennett M, Macdonald K, Chen SW, Luzio JP, Simari R, Weissberg P (1998) Cell surface trafficking of Fas: a rapid mechanism of p53- mediated apoptosis. Science 282:290-293
7. Balogh GA, Mailo DA, Corte MM, Roncoroni P, Nardi H, Vincen E et al (2006) Mutant p53 protein in serumcould be used as amolecular marker in human breast cancer. Int J Oncol 28:995-1002
8. Duffy MJ (1999) CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 36:579-586
9. Keyhani M, Nasizadeh S, Dehghannejad A (2005) Serum CA 15-3 measurment in breast cancer patients before and after mastectomy. Arch Iranian Med 8:263-266
10. Haskell CM, Lowitz BB, Casciato AD (1985) Breast cancer. In: Casciato AD, Lowitz BB (eds) Manual of clinical oncology, 2nd edn. Little and Brown, Boston, pp 150-165
11. Rintoul RF (1986) Operations on the breast. In: Farquhaerison,s text book of operative surgery, 7th ed. Churchill living stone (pub.) 270-281
12. AbeloffMD, Lichter AS, Niederhuber JE, Pierce LJ, Aziz DC (1995) Breast. In: Abeloff MD, Armitage JO, Licher AS, Niederhuber JE (eds) Clinical Oncology, Churchil livingstone Inc. (Pub.) 1617-714
13. Munakata S, Watanabe O, Ohashi K, Morino H (2005) Expression of Fas ligand and bcl-2 in cervical carcinoma and their prognostic significance. Am J Clin pathol 123:879-885
14. Zhang L, Levi E, Majumder P, Yu Y, Aboukameel A, Du J (2007) Transactivator of transcription tagged cell cycle and apoptosis regulatory protein-1 peptides suppress the growth of human breast cancer cells in vitro and in vivo. Mol cancer Ther 6:1661-1672
15. Motyl T, Gajkowska B, Zarzy J, Gajewska M, Lamparska P (2006) Apoptosis and autophagy in mammary gland remodeling and breast cancer chemotherapy. J Physiol Pharmacol 7:17-32
16. Habibagahi M, Jaberipour M, Fattahi MJ, Hashemi SB, Shariati M (2010) High concentration of serum soluble Fas in patients with head and neck carcinoma: a comparative study before and after surgical removal of tumor. Middle East J Can 1:21-26
17. El-Sarha A, Magour G, Zaki S, El-Sammak M (2009) Serum sFas and tumor tissue FasL negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma. Pathol Oncol Res 15:241-250
18. Ohbu M, Saegusa M, Okayasu I (1995) Apoptosis and cellular proliferation in oesophageal squamous cell carcinoma: differences between keratinizing and nonkeratinizing types. Virchows arch 427:271-276
19. Pignataro L, Arisi E, Sambataro G, Corsi MM (2003) Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment. J Sur Oncol 83:112-115
20. Ugurel S, Rappl G, TilgenW, Reinhold U (2001) Increased soluble CD95(sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 7:1282-1286
21. Shimizu M, Kondo M, Ito Y, Kume H, Suzuki R, Yamaki K (2005) Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients. Canc Detect Prev 29:175-180
22. Iwase M, Kondo G, Watanabe H, Takaoka S, Uchida M, Ohashi M et al (2006) Regulation of Fas-mediated apoptosis in neutrophils after surgery-induced acute inflammation. J Surg Res 134:114-123
23. Paunel-Gorgulu A, Flohe S, Scholz M, Windolf J, Logters T (2011) Increased serum soluble Fas after major trauma is associated with delayed neutrophil apoptosis and development of sepsis. Critical care 15:R20
24. Donnelly SC, MacGregor I, Zamani A, Gordon MW, Robertson CE, Steedman DJ et al (1995) Plasma elastase levels and the development of the adult respiratory distress syndrome. Am J Respir Crit Care Med 151:1428-1433
25. Bhatia R, Dent C, Topley N, Pallister I (2006) Neutrophil priming for elastase release in adult blunt trauma patients. J Trauma 60:590-596
26. Nadal C, Maurel J, Gallego R, Castells A, Longarón R, Marmol M et al (2005) Fas/Fas ligand ratio: a marker of Oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. Clin Cancer Res 11:4770-4774
27. Hewala TI, Abd EL-Moneim NA, Ebied SA, Sheta MI, Soliman K, Abu-ELenean A (2010) Diagnostic and prognostic value of serum nitric oxide, tumor necrosis factor-a, basic fibroblast growth factor and copper as angiogenic markers in premenopausal breast cancer patients: a case-control study. BJBS 67:167-176
28. Gion M, Mione R, Leon AE, Dittadi R (1999) Comparison of the diagnostic accuracy of CA27.29 and CA15-3 in primary breast cancer. Clin Chem 45:630-637
29. Duffy MJ (2006) Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52:345-351